Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 2

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 3(3)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00520780Phase 3Completed

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

Role: collaborator

NCT03717272Phase 2Completed

Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

Role: collaborator

NCT02130063Phase 3Completed

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

Role: collaborator

NCT01097668Phase 1Completed

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Role: collaborator

NCT00810030Phase 3Completed

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

Role: collaborator

All 5 trials loaded